Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 12/20 | 0.55 |
| ▸ | KDR | P35968 | 4/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239105 | 0.84 | RAF1 (0.52) | RAF1KDRPDGFRBBRAFCSF1R | |
| SCHEMBL12424677 | 0.78 | KDR (0.59) | KDRPDGFRBCSF1RKITFLT1 | |
| SCHEMBL3851409 | 0.77 | RAF1 (0.54) | RAF1KDRPDGFRBBRAFCSF1R | |
| SCHEMBL2236827 | 0.77 | KDR (0.78) | RAF1KDRPDGFRBBRAFCSF1R | |
| SCHEMBL2235566 | 0.76 | KDR (0.59) | KDRPDGFRBCSF1RKITFLT1 | |
| SCHEMBL2238477 | 0.76 | DYRK3 (0.47) | RAF1BRAFNAMPTCHEK1 | |
| SCHEMBL5445313 | 0.75 | RAF1 (0.60) | RAF1KDRBRAF | |
| SCHEMBL4247303 | 0.74 | MEN1 (0.64) | RAF1BRAF | |
| SCHEMBL3476076 | 0.74 | RAF1 (0.61) | RAF1BRAF | |
| SCHEMBL4243486 | 0.74 | RAF1 (0.61) | RAF1KDRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008322-B2 | Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use | AVENTIS PHARMA S.A. (FR) | 2011-08-30 | — | — | US | disclosed |
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A.. (FR) | 2011-08-04 | — | — | US | disclosed |
| EP-1845978-B1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | disclosed |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2008-02-14 | — | — | US | disclosed |
| EP-1845978-A1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | Aventis Pharma S.A. (FR) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006077319-A1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | DPYD, TYMP, PCK2 | RAF1 541/4885KDR 2947/4885PDGFRB 1523/4885 |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | DPYD, TYMP, PCK2 | RAF1 541/4885KDR 2947/4885PDGFRB 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.